What is IBIO (IBIO) stock price today?

IBIO (IBIO) is currently trading at $1.45, up 1.4% today.

What is IBIO P/E ratio?

IBIO's P/E ratio is -0.91. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is IBIO return on equity (ROE)?

IBIO's return on equity (ROE) is -120.00%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is IBIO's market cap?

IBIO has a market capitalization of $22.89M.

NASDAQ · Biotechnology

IBIO (IBIO) Stock

$1.45 +1.40% NASDAQ: IBIO Healthcare

Valuation

Metric	Value
Price	$1.45
Market Cap	$22.89M
P/E Ratio	-0.91
P/B Ratio	1.68
P/S Ratio	74.74
EPS (TTM)	$-1.75
52-Week High	$3.82
52-Week Low	$0.56
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-120.00%
ROA	-78.26%
ROCE	-126.67%
Gross Margin	-1.60%
Operating Margin	-79.85%
Net Margin	-92.02%
Debt/Equity	0.03
Current Ratio	1.67

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$2.0M	$2.0M	$0	$0	$0
Operating Profit	$-31.0M	$-30.0M	$-29.0M	$-17.0M	$-19.0M
Net Profit	$-23.0M	$-50.0M	$-65.0M	$-25.0M	$-18.0M
EPS	$-59.98	$-2889.06	$-106.18	$-6.50	$-1.75
Op Margin	-1312.2%	-1576.3%	—	-7392.9%	-4650.5%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$147.0M	$99.0M	$41.0M	$29.0M	$23.0M
Total Liabilities	$38.0M	$36.0M	$26.0M	$7.0M	$8.0M
Cash	$77.0M	$23.0M	$7.0M	$14.0M	$9.0M
Borrowings	$33.0M	$26.0M	$17.0M	$4.0M	$4.0M

Latest News

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study GlobeNewswire · Jul 1, 2026 Could iBio (IBIO) Be an Underrated Obesity Stock? Insider Monkey · Jun 12, 2026 B. Riley Initiates iBio at Buy With $6 Price Target MT Newswires · Jun 5, 2026 iBio to Participate in Upcoming Healthcare Investor Conferences GlobeNewswire · Jun 2, 2026 iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity GlobeNewswire · Jun 2, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-30.0M	$-38.0M	$-30.0M	$-19.0M	$-15.0M
Investing Cash Flow	$-32.0M	$-12.0M	$1.0M	$1.0M	$1.0M
Financing Cash Flow	$1.0M	$0	$0	$0	$0
Net Cash Flow	$22.0M	$-55.0M	$-21.0M	$7.0M	$-6.0M
Free Cash Flow	$-35.0M	$-45.0M	$-36.0M	$-19.0M	$-15.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-98.86%
Quick Ratio	11.88
Interest Coverage	—
Return 1Y	98.61%
Return 3Y	-87.23%
Return 5Y	-99.78%

Ownership

Insiders Held1.71%

Institutions Held48.65%

Institutions Float Held49.50%

Institutional Holder	Shares	Report Date
Affinity Asset Advisors, Llc	3,107,200	2026-03-31
Frazier Life Sciences Management, L.P.	1,953,467	2026-03-31
EcoR1 Capital, LLC	1,583,000	2026-03-31
Millennium Management Llc	1,549,850	2026-03-31
Logos Global Management LP	1,300,000	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ANTX	$4.93	+0.20%	-4.76	$177.56M	0.00%
BOLD	$2.48	-3.50%	-0.56	$55.74M	0.00%
CVKD	$2.06	+0.98%	-0.78	$6.38M	0.00%
INTS	$4.57	+2.70%	-0.60	$12.35M	0.00%
ITRMIterum Therapeutics plc	$0.03	-10.98%	-0.06	$1.60M	0.00%

About IBIO

IBIO is led by CEO Martin Brenner, employs 16 people, headquartered in US, publicly traded since 2008.

IBIO stock trades at $1.45 with a market capitalization of $22.89M. The stock is valued at a price-to-earnings (P/E) ratio of -0.91, price-to-book of 1.68, price-to-sales of 74.74. Over the past 52 weeks the stock has ranged between $0.56 and $3.82, and currently trades 62.0% below its 52-week high.

On profitability, IBIO generates a return on equity (ROE) of -120.00%, return on capital employed of -126.67%, an operating margin of -79.85%, a net profit margin of -92.02%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides